1. Healthcare

PRELIMINARY PROGRAMME
Masterclass in
molecular oncology
29-31 January 2015 - Prague, Czech Republic
Dear delegate,
A warm welcome to all attending the “Masterclass in molecular
oncology”.
I would like to inform you that as of 28 April 2014 the name of our
Foundation changed to EXCEMED – Excellence in Medical Education.
The name change will not impact your registration status in this or any
other Foundation event.
This transition marks an exciting point in the evolution of the Foundation.
We are proud to have provided world-class education to thousands of
healthcare professionals over the past four decades - as a result, the
Foundation has become synonymous with delivery excellence and highimpact CME.
As we further develop our scientific and geographical presence it is
important to us that our name accurately reflects the independent
nature of the education we provide; EXCEMED symbolises our enduring
mission to support the best possible outcomes for patients through the
medical education we offer. We take pride in our complete dedication to
the provision of CME - it is our sole focus and our passion.
I wish you an inspiring and successful learning experience here in
Prague.
Yours sincerely,
Rachel Clark
CEO, EXCEMED
1
Aim
Precision medicine in oncology is an evolving landscape. In recent years
new insights have been gained into driver genomic alterations
responsible for cancer progression. The identification of a growing
number of molecular targets and the availability of specific targeted
therapies are fueling the clinical research and rapidly changing clinical
practice. The aim of this masterclass in molecular oncology is to
describe the basic principles of cancer genomics, techniques in
molecular biology and translational research. This live educational
intensive course will provide insights into the new taxonomy of cancer,
the molecular pathways relevant for therapy and the methodology in
molecular diagnosis of cancer.
Educational Format
This highly interactive course is designed to deliver effective knowledge
in molecular oncology. The aim is to make the expertise of recognized
key opinion leaders available to the learners, providing them with the
opportunity to clarify doubts and solve uncertainties in the field of
molecular oncology. For this purpose, the educational format will be
based on a series of lessons, followed by direct interactions among
experts and learners, during the curricular activities in the meeting
rooms and outside.
Learning objectives
After attending this masterclass in molecular oncology learners will be
able to:
• Define relevant molecular pathways in oncology
• Distinguish genome analysis methods
• Illustrate personalized treatment options for cancer patients
Target audience
Medical oncologists who want to improve their knowledge in molecular
biology platforms for targeted therapy and drug discovery.
2
Accreditation
An application will be made to the EACCME® for CME accreditation of
this EXCEMED live educational course “Masterclass in molecular
oncology” to be held on 29-31 January 2015 in Prague, Czech Republic.
An application has been made to the ESMO for CME accreditation.
EXCEMED adheres to the principles of the Good CME Practice Group
(gCMEp).
Register to EXCEMED website:
www.oncology.excemed.org
follow us on
EXCEMED_Onco
http://twitter.com/EXCEMED_Onco
3
Chairmen and coordinators of
the steering committee
Eric Van Cutsem
University Hospitals Gasthuisberg / Leuven
Leuven, Belgium
Yosef Yarden
Weizmann Institute of Science
Department of Biological Regulation
Rehovot, Israel
Share your opinion with us
We are always looking for ways to bring our educational activities
to the next level and meet your needs as a healthcare practitioner.
You will be asked to answer a post-event online survey to find out if
the experience met your educational expectations. Your views also
help us tailor future initiatives.
Thank you for taking the time to participate.
Scientific secretariat
EXCEMED - Excellence in Medical Education
Salita di San Nicola da Tolentino, 1/b
00187 Rome, Italy
Programme Manager: Giovanna Rossi
T +39 06 420 413 252 - F +39 06 420 413 677
E-mail: [email protected]
Specialist Medical Advisor: Cristina Raimondi
EXCEMED is a Swiss Foundation with headquarters in
14, Rue du Rhône, 1204 Geneva, Switzerland
Organising secretariat
Meridiano Congress International
Via Sapri, 6 - 00185 Rome, Italy
Congress Coordinator: David H. Slangen
T +39 06 88 595 250 - F +39 06 88595 234
E-mail: [email protected]
5
Faculty members
Ahmad Awada
Medical Oncology Clinic
Jules Bordet Institute
Brussels, Belgium
Alberto Bardelli
Univeristy of Torino
School of Medicine
Turin, Italy
Fortunato Ciardiello
Division of Medical Oncology
Department of Experimental and
Clinical Medicine and
Surgery F. Magrassi and A. Lanzara
Second University of Naples
Naples, Italy
Rolf Stahel
University Hospital Zürich
Zürich, Switzerland
Josep Tabernero
Vall d’Hebron University Hospital
Vall d'Hebron Institute of Oncology (VHIO)
Barcelona, Spain
Eric Van Cutsem
University Hospitals Gasthuisberg/Leuven
Leuven, Belgium
Yosef Yarden
Weizmann Institute of Science
Department of Biological Regulation
Rehovot, Israel
Christoph C. Zielinski
Comprehensive Cancer Center, Vienna
General Hospital and Medical University of Vienna
Vienna, Austria
Central European Cooperative Oncology Group (CECOG)
6
Xxxxxx
Xxxxx xxxxxxxxxxx
Scientific
programme
Scientific programme
Thursday, 29 January 2015
Session I
Evening session
18.00 Welcome and presentation of the Masterclass course
E. Van Cutsem (Belgium) - Y. Yarden (Israel)
18.15 Opening keynote lecture:
Overview on relevant molecular pathways in oncology
and their pharmacological intervention
Speaker to be announced
19.00 Get together dinner
End of the first day
8
Friday, 30 January 2015
Session II
Optional early bird session
07.30 Genome analysis methods (basics)
Y. Yarden (Israel)
Session III
09.00 Basics of signal transduction (terminology and specific
examples)
A. Bardelli (Italy)
09.30 Signal transduction pathways I: the HER family
C. Zielinski (Austria)
10.00 Signal transduction pathways II: mTOR-PI3K
Speaker to be announced
10.30 Signal transduction pathways III: RAS-RAF-MEK
F. Ciardiello (Italy)
11.00 Coffee break
11.30 Genome analysis methods (advanced)
Y. Yarden (Israel)
12.00 Biomarkers based on proteomics and high-resolution
genomics/transcriptomics
Speaker to be announced
12.30 Extended lunch break
Poster viewing and oral poster presentations
9
Scientific programme
Session IV
14.30 Controversies and panel discussion I:
Cancer stem cells
Moderators: Y. Yarden (Israel) - F. Ciardiello (Italy)
15.15 Controversies and panel discussion II:
Tumor heterogeneity and relevance to acquired
resistance to targeted therapies
Moderator: J. Tabernero (Spain)
16.00 Coffee break
16.30 Essential of pharmacology of the old and new drugs
A. Awada (Belgium)
17.00 The next generation of molecular targeted therapies
R. Stahel (Switzerland)
17.30 End of the second day
Session V
Optional evening session: exercises
19.30 Science-medicine tutorials
(breakthough scientific publications will be presented
and discussed)
Mentors:
E. Van Cutsem (Belgium)
Y. Yarden (Israel)
20.30 Dinner
10
Saturday, 31 January 2015
Session VI
Optional early bird session
17.30 Liquid biopsy in oncology
J. Tabernero (Spain)
Session VII
Parallel sessions
09.00 Parallel sessions
 Breaking news: breast cancer
C. Zielinski (Austria)
 Breaking news: colorectal cancer
E. Van Cutsem (Belgium)
 Breaking news: lung cancer
0
R. Stahel (Switzerland)
10.30 Coffee break
10.50 Key messages from the parallel sessions
Session VIII
11.35 Design of clinical trials in the era of targeted agents:
theory and practice
F. Ciardiello (Italy)
12.25 Extended lunch break
Poster viewing and oral poster presentations
14.25 Closing keynote lecture:
Cancer immunology and immunotherapy: clinical
application in melanoma
Speaker to be announced
15.10 Closing remarks and end of the Masterclass course
11
Call for abstracts
In the spirit of supporting the dissemination of diverse oncological
research, the Steering Committee is pleased to invite the submission of
abstract proposals for oral and poster presentations.
Authors are requested to send their abstract via e-mail by 20 October 2014
to the following address: [email protected]
Topic choices
A. Signal transduction pathways in oncology
B. Precision medicine in breast, colorectal and lung cancer
Submission procedure
Abstracts must be written in English and should not exceed 300 words.
Abstract format: Title, Authors, Affiliations, Main text including
background, aims, materials and methods, results and conclusions.
The abstract should be structured as follows:
Introduction: an informative and short background of the study
Aims: outlining the main hypothesis and objectives of the study
Material and Methods: indicating the number, nature and type of cohorts
or material being studied, as well as the main procedures, assays, tests or
treatments performed for it
Results: showing the main results obtained, confirming or refuting the
initial hypothesis, supported by statistics if appropriate
Conclusions: stating the key learning points of the study
• Abbreviations can be used after defining them first. The abstract title
should reflect the contents and should be no longer than 150 characters.
• List the authors with family name first, followed by initials. The name of
the first author is also the presenting author. Use font size 12, Times
New Roman font, and line spacing 1.5.
• Authors are requested to disclose any financial support received and/or
any potential conflict of interest at the end of the abstract.
The Scientific Committee will review the submitted abstracts choosing the
best abstracts for oral or poster presentation. The selected abstracts will
be published in the abstract book to be distributed on-site to all
participants.
12
Young (less than 5 years of activity in primary profession) medical
oncologists whose abstract is selected for oral and poster presentations
will receive a grant for their registration fee. Young medical oncologists
coming from Eastern Europe (Albania, Armenia, Azerbaijan, Belarus,
Bosnia and Herzegovina, Bulgaria, Croatia, the Czech Republic, Georgia,
Hungary, Kosovo, Macedonia, Moldova, Montenegro, Poland, Romania,
Russia, Serbia, Slovakia, Slovenia, and Ukraine) who submit an abstract
may also apply for a travel grant of € 500.
EXCEMED will reward the authors of the four abstracts selected for oral
presentation with a grant of € 1,000. The value of this award will be given
as a voucher to be spent on participating in CME (Continuing Medical
Education) courses and congresses no later than December 2015 as
defined with the winner in agreement with EXCEMED.
Notification of accepted abstracts will be sent by the first week of
December 2014.
13
General information
Venue
This live educational course will take place at the:
Park Inn Hotel Prague
Svobodova 1
128 00 Prague, Czech Republic
Tel. +420 225 995 225
Language
The official language of this live educational course will be English.
Registration fee
 The registration fee is . . . . . . . . . . . . . . . . . . . . . . . . . . . . € 500.00.
 The registration fee for ESMO members is . . . . . . . . . . . € 375.00.
This fee includes:
- Scientific sessions
- Educational materials
- Coffee breaks and luncheons
- Dinner on 29 January
- Dinner on 30 January
- Certificate of attendance
For any information on accommodation and registration fees please
contact:
David H. Slangen c/o Meridiano Congress International
T +39 06 88 595 250 - F +39 06 88595 234
E-mail: [email protected]
14
Take a look at the oncology section
of the EXCEMED website
EXCEMED has made a strong commitment to medical education in
oncology and is developing live events such as workshops, expert
meetings and preceptorships, online activities, and other
programmes that will focus on key issues in oncology and the
multidisciplinary approaches to patient management.
Visit the oncology section:
www.oncology.excemed.org
and register to access free e-learning activities and receive updates
on new events and resources.
All EXCEMED programmes are organized solely to promote the exchange and
dissemination of scientific and medical information. No forms of promotional
activities are permitted. This programme is made possible thanks to educational
grants received from: Arseus Medical, Besins Healthcare, Bristol-Myers Squibb,
Celgene, Centre d’Esclerosi Multiple de Catalunya (Vall d’Hebron University
Hospital), Centre Hépato-Biliaire (Hôpital Paul Brousse), Croissance Conseil, CryoSave, Datanalysis, Dos33, Esaote, Ferring, Fondazione Humanitas, Fundación IVI,
GE Healthcare, GlaxoSmithKline Pharmaceuticals, IPSEN, Italfarmaco, Johnson &
Johnson Medical, K.I.T.E., Karl Storz, Lumenis, Merck Serono Group, PregLem,
Richard Wolf Endoscopie, Sanofi-Aventis, Stallergenes, Stopler, Teva Pharma,
Toshiba Medical Systems, Université Catholique de Louvain (UCL), University of
Catania.
Improving the patient's life through medical education
www.excemed.org
EXCEMED - Excellence in Medical Education
Headquarters
14, Rue du Rhône - 1204 Geneva, Switzerland
Representative Office
Salita di San Nicola da Tolentino 1/b - 00187 Rome, Italy
T +39 06 420413 1 - F +39 06 420413 677
Copyright © EXCEMED, 2014. All rights reserved.